首页> 美国卫生研究院文献>Journal of Diabetes Science and Technology >Personalized Medicine for Diabetes: Personalized Medicine in Diabetes: Regulatory Considerations
【2h】

Personalized Medicine for Diabetes: Personalized Medicine in Diabetes: Regulatory Considerations

机译:糖尿病的个性化药物:糖尿病的个性化药物:监管方面的考虑

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Personalized medicine has become a topic of great interest because of its potential to improve patient care and optimize therapeutic strategy. The U.S. Food and Drug Administration (FDA) is interested in promoting personalized medicine, whenever appropriate, to protect and promote the public health. The ability to better diagnose, screen, and manage patients with diabetes in order to individualize care should lead to better health outcomes and a large benefit to public health. This article describes FDA regulatory considerations for devices intended for use as personalized medicine tools for the diagnosis and treatment of patients with diabetes.
机译:个性化医学因其改善患者护理和优化治疗策略的潜力而备受关注。美国食品药品监督管理局(FDA)有兴趣在适当的时候推广个性化药物,以保护和促进公众健康。更好地诊断,筛查和管理糖尿病患者以进行个性化护理的能力应会带来更好的健康结果,并为公共健康带来巨大好处。本文介绍了FDA法规考虑的设备,这些设备旨在用作诊断和治疗糖尿病患者的个性化医疗工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号